6 / 46
4
t h
E u r o S c i C o n C o n f e r e n c e o n
Neurology & Neurological
Disorders
Neurology 2018
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
Page 68
Journal of Neurology and Neuroscience
ISSN: 2171-6625
T
he aim of the present study is formulation of solid lipid nanoparticles
(SLNs) containing combination of bromocriptine and resveratrol for
effective management of Parkinson Disease. The goal of this therapeutic
strategy is to reduce the occurrence and severity of L- DOPA (LD) associated
motor fluctuations and dyskinesia, and providing good long-term safety
and tolerability. Dopamine agonists such as bromocriptine provide
moderate symptomatic benefit and delay the development of dyskinesia
compared with levodopa. Resveratrol is a natural polyphenolic compound
suggesting that they could have important antioxidant properties and
resveratrol could possibly reduce the side effects of bromocriptine but its
oral bioavailability is very low due to its extensive hepatic and presystemic
metabolism. One of the prime benefits of combination therapy is the
potential for providing synergistic effects. However, bromocriptine suffers
from low bioavailability and short half-life. Therefore, it would be a good
candidate for a sustained drug-delivery system. SLNs were prepared using
high speed homogenization followed by ultrasonication technique. The
prepared SLNs were characterized by entrapment efficiency percent (EE
%), particle size distribution, zeta- potential, and cumulative percentage
release. The mean particle size measured ranged from 100-220 nm. The
EE % ranged between 81.00±0.92% - 92.52±0.10%. Smaller size and narrow
size range allows them to cross tight endothelial cells of the blood–brain
barrier (BBB), escape from the reticuloendothelial system (RES), and
bypass liver. They have comparatively higher drug entrapment efficiency,
render the drug more stable in their lipid matrix, and provide a controlled
release lasting up to several weeks. The prepared SLNs exhibited a
zero-order sustained release profile and met the requirement for a brain
targeting; hence it could be a promising strategy to deliver bromocriptine
to the brain.
Dual drug-loaded lipid nanoparticles for the treatment of
Parkinson’s disease
Asha Spandana K M
1
, Jawahar Natarajan
2
and Mahendran
Baskaran
1
1
JSS College of Pharmacy, JSS Academy of Higher Education and Research, Mysore, India
2
JSS College of Pharmacy, Ootacamund, India
Asha Spandana K M et al., J Neurol Neurosci 2018, Volume: 9
DOI: 10.21767/2171-6625-C1-009
Biography
Asha Spandana K M is currently pursuing her PhD in Pharmaceutical
Sciences in the area of Brain Targeted Drug Delivery System at JSS
University, Mysore, India. She accomplished her Undergraduation
from JSSCP, Mysore under RGUHS, Bengalore in 2010 and M Pharm in
Pharmaceutics from RGUHS, Bengaluru, under merit (GPAT-qualified) in
2013. She has published 4 papers in national and international level.
asha@jssuni.edu.in